Based on a review of data in the noted references, the panel voted on adding dabrafenib/trametinib combination therapy as an option for patients with BRAF-V600 activating mutation in the following adjuvant treatment settings:

1. Resected stage III sentinel node positive melanoma (ME-4)
   a. Panel vote supported that the addition of dabrafenib/trametinib as a treatment option for patients with SLN metastasis >1 mm is supported by high-level evidence (category 1)

2. Resected stage III disease with clinically positive node(s) (ME-5)
   a. Panel vote supported that the addition of dabrafenib/trametinib as a treatment option is supported by high-level evidence (category 1)

3. Resected stage III clinical satellite or in-transit melanoma (ME-7)
   a. Panel vote supported the addition of dabrafenib/trametinib as a treatment option

4. Resected local, satellite, and/or in-transit melanoma (ME-12)
   a. Panel vote supported the addition of dabrafenib/trametinib as a treatment option

5. After complete lymph node dissection and/or a complete resection of a nodal recurrence of melanoma (ME-13)
   a. Panel vote supported that the addition of dabrafenib/trametinib as a treatment option is supported by high-level evidence (category 1)